Cellular Biomedicine Group is a biopharmaceutical company that develops treatments for cancerous and degenerative diseases. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The Company develops treatments utilizing proprietary cell-based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell-specific dendritic cell therapy.

Employee Rating

5.0More
TypePublic
HQCupertino, US
Founded2009
Size (employees)125 (est)+15%
Websitecellbiomedgroup.com
Cellular Biomedicine Group was founded in 2009 and is headquartered in Cupertino, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Cellular Biomedicine Group Office Locations

Cellular Biomedicine Group has offices in Cupertino, Beijing, Shanghai and Hong Kong
Cupertino, US (HQ)
100 19925 Stevens Creek Blvd
Beijing, CN
Nongda South Road
Shanghai, CN
333 Guiping Road
Hong Kong , HK
No. 8 Cotton Tree Drive
Show all (4)
Report incorrect company information

Cellular Biomedicine Group Financials and Metrics

Cellular Biomedicine Group Revenue

Cellular Biomedicine Group's revenue was reported to be $336.82 k in FY, 2017
USD

Revenue (Q3, 2018)

70.4k

Gross profit (Q3, 2018)

32.9k

Gross profit margin (Q3, 2018), %

46.8%

Net income (Q3, 2018)

(12.7m)

EBIT (Q3, 2018)

(12.8m)

Market capitalization (14-Dec-2018)

355.1m

Closing stock price (14-Dec-2018)

19.3

Cash (30-Sep-2018)

57.9m
Cellular Biomedicine Group's current market capitalization is $355.1 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

2.5m627.9k336.8k

Cost of goods sold

1.9m860.4k162.2k

Gross profit

625.1k(232.5k)174.6k

Gross profit Margin, %

25%(37%)52%
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

111.4k603.4k657.0k624.9k488.5k71.6k10.0k98.4k62.9k106.8k51.0k77.3k70.4k

Cost of goods sold

158.3k52.0k459.0k398.2k443.4k503.2k323.6k9.1k37.4k38.1k55.3k22.3k54.4k37.5k

Gross profit

144.4k258.7k181.5k(14.7k)(252.0k)884.061.0k24.8k51.5k28.7k22.9k32.9k

Gross profit Margin, %

24%39%29%(3%)(352%)9%62%39%48%56%30%47%
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Cash

7.2m14.9m39.3m21.6m

Accounts Receivable

10.6k630.3k412.7k

Inventories

119.1k390.9k

Current Assets

7.6m16.7m40.7m24.5m
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

4.9m2.1m3.5m6.0m13.6m9.8m31.1m23.7m20.1m15.7m47.5m44.1m33.4m27.3m16.3m45.6m24.8m57.9m

Accounts Receivable

34.6k24.0k175.1k340.0k445.2k410.8k582.7k245.1k264.8k813.1k

Inventories

38.8k30.4k40.0k133.7k156.5k347.8k277.9k400.1k422.1k486.3k313.8k253.2k

Current Assets

5.2m2.5m3.8m6.6m14.2m11.1m32.6m25.5m21.7m17.7m49.2m45.3m35.3m29.4m19.1m48.7m37.5m70.3m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(13.8m)(19.4m)(28.2m)(25.5m)

Depreciation and Amortization

841.2k2.1m2.6m3.0m

Inventories

(81.9k)(142.5k)514.7k

Accounts Payable

(166.0k)(28.2k)(814.0)
Quarterly
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Cellular Biomedicine Group Online and Social Media Presence

Embed Graph
Report incorrect company information

Cellular Biomedicine Group News and Updates

Cellular Biomedicine Group Enters Into Strategic Licensing and Collaboration Agreement with a Global Leader in CAR-T Cell Therapy for Patients in China

SHANGHAI and CUPERTINO, Calif., Sept. 27, 2018 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) today announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in ...
Report incorrect company information

Cellular Biomedicine Group Blogs

CBMG to Present on Three Panels at B. Riley FBR Annual Healthcare Conference

Cellular Biomedicine Group to Present on Three Panels at B. Riley FBR Annual Healthcare Conference  SHANGHAI, China and CUPERTINO, Calif., August 28, 2018 (GLOBE NEWSWIRE) — Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in t…

Second Quarter and First Half 2018 Financial Results and Business Highlights

Cellular Biomedicine Group Reports Second Quarter and First Half 2018 Financial Results and Business Highlights   China Food and Drug Administration (CFDA) Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19 CAR-T TherapyTargeting NHL and ALL Moved to New R&D Center i…

CBMG Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland

Cellular Biomedicine Group Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland SHANGHAI, China and CUPERTINO, Calif., June 22, 2018 (GLOBE NEWSWIRE) — Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical …

CBMG to Present a Keynote Address at CAR-TCR Summit Asia

CBMG to Present a Keynote Address at CAR-TCR Summit Asia SHANGHAI, China and CUPERTINO, Calif., June 21, 2018 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell thera…

Cellular Biomedicine Group Company Life and Culture

Report incorrect company information

Cellular Biomedicine Group Frequently Asked Questions

  • When was Cellular Biomedicine Group founded?

    Cellular Biomedicine Group was founded in 2009.

  • How many employees does Cellular Biomedicine Group have?

    Cellular Biomedicine Group has 125 employees.

  • What is Cellular Biomedicine Group revenue?

    Latest Cellular Biomedicine Group annual revenue is $336.8 k.

  • What is Cellular Biomedicine Group revenue per employee?

    Latest Cellular Biomedicine Group revenue per employee is $2.7 k.

  • Who are Cellular Biomedicine Group competitors?

    Competitors of Cellular Biomedicine Group include Carrick Therapeutics, Galectin Therapeutics and Replimune.

  • Where is Cellular Biomedicine Group headquarters?

    Cellular Biomedicine Group headquarters is located at 100 19925 Stevens Creek Blvd, Cupertino.

  • Where are Cellular Biomedicine Group offices?

    Cellular Biomedicine Group has offices in Cupertino, Beijing, Shanghai and Hong Kong.

  • How many offices does Cellular Biomedicine Group have?

    Cellular Biomedicine Group has 4 offices.